Blackrock Neurotech is a leading developer of implantable brain-computer interface (BCI) technology, best known for the Utah Array — the most widely used invasive neural electrode array in clinical research. Founded in 2008 and headquartered in Salt Lake City, Utah, Blackrock has established itself as a pioneer in high-density electrophysiology recording and stimulation systems for neurological applications.
Overview
Blackrock Neurotech — Brain-Computer Interface is a therapeutic candidate being investigated for the treatment of neurodegenerative diseases. This page provides comprehensive information on its mechanism of action, clinical development status, and therapeutic potential.
Technology Platform
Utah Array
The Utah Array is a silicon-based microelectrode array designed for chronic implantation in the motor cortex and other brain regions. Key characteristics include[@blackrocka]:
96 recording sites arranged in a 10×10 grid (with center electrode removed)
1.5 mm electrode length (standard) — penetrates cortical layers
Bio-compatible coating — parylene-C insulation
Chronic stability — demonstrated functional for 10+ years in humans
High signal quality — single-unit action potential recording
Blackrock MicroPort
The next-generation Blackrock MicroPort represents an evolution of the Utah Array platform with improved characteristics[@blackrockb]:
...
Blackrock Neurotech is a leading developer of implantable brain-computer interface (BCI) technology, best known for the Utah Array — the most widely used invasive neural electrode array in clinical research. Founded in 2008 and headquartered in Salt Lake City, Utah, Blackrock has established itself as a pioneer in high-density electrophysiology recording and stimulation systems for neurological applications.
Overview
Blackrock Neurotech — Brain-Computer Interface is a therapeutic candidate being investigated for the treatment of neurodegenerative diseases. This page provides comprehensive information on its mechanism of action, clinical development status, and therapeutic potential.
Technology Platform
Utah Array
The Utah Array is a silicon-based microelectrode array designed for chronic implantation in the motor cortex and other brain regions. Key characteristics include[@blackrocka]:
96 recording sites arranged in a 10×10 grid (with center electrode removed)
1.5 mm electrode length (standard) — penetrates cortical layers
Bio-compatible coating — parylene-C insulation
Chronic stability — demonstrated functional for 10+ years in humans
High signal quality — single-unit action potential recording
Blackrock MicroPort
The next-generation Blackrock MicroPort represents an evolution of the Utah Array platform with improved characteristics[@blackrockb]:
Smaller footprint with higher electrode density
Improved chronic reliability
Higher spatial resolution for fine-grained neural decoding
Compatible with the Utah Slant Array (variant with staggered electrode lengths)
Neural Processing Pipeline
Blackrock systems integrate sophisticated signal processing:
Signal Acquisition — Amplification, filtering, digitization
Spike Sorting — Isolation of individual neuron activity
Feature Extraction — Population firing rates, LFP spectral features
Decoding Algorithms — Kalman filters, neural networks for movement prediction
Clinical Applications
BrainGate Clinical Trial
Blackrock technology powers the landmark BrainGate clinical trial — one of the most advanced BCI human studies[@willett2021][@hochberg2012]:
Trial ID: NCT00912041
Participants: Individuals with tetraplegia due to spinal cord injury or brainstem stroke
Results:
Cursor control with thought alone
Click-through with >90% accuracy
Robotic arm control for self-feeding
Typing speeds up to 8 words/minute
Amyotrophic Lateral Sclerosis (ALS)
Blackrock BCIs offer significant potential for ALS patients[@woolsey2021]:
Communication restoration in locked-in state
Environmental control (smart home integration)
Respiratory monitoring and alert systems
Parkinson's Disease
[Parkinson's Disease](/diseases/parkinsons-disease) research applications include[@little2013]:
[Adaptive deep brain stimulation](/treatments/deep-brain-stimulation) systems
Tremor prediction algorithms
Closed-loop therapeutic interventions
Potential for [neuroprotective](/therapeutics/neuroprotective-therapy) interventions
Competitive Landscape
| Feature | Blackrock Utah Array | Neuralink N1 | Synchron Stentrode | |---------|---------------------|--------------|-------------------| | Invasiveness | Highly invasive (craniotomy) | Minimally invasive (craniotomy) | Minimally invasive (endovascular) | | Electrode Count | 96-128 | 1,024 | 16 | | Bandwidth | High | Very high | Moderate | | Clinical Status | FDA IDE approved | FDA IDE approved | FDA IDE approved | | Chronic Use | 10+ years | <3 years | <2 years | | Applications | [ALS](/diseases/amyotrophic-lateral-sclerosis), [PD](/diseases/parkinsons-disease), [BCI](/technologies/brain-computer-interface) | [ALS](/diseases/amyotrophic-lateral-sclerosis), [PD](/diseases/parkinsons-disease), tetraplegia | [Stroke](/diseases/stroke), [ALS](/diseases/amyotrophic-lateral-sclerosis) |
Regulatory Status
FDA Investigational Device Exemption (IDE): Approved for [chronic implantation](/therapeutics/implantable-neurotechnology)
Breakthrough Device Designation: Granted for communication restoration in [locked-in patients](/diseases/locked-in-syndrome)
Humanitarian Use Device (HUD): Approved for specific [neurological indications](/diseases/neurodegenerative-disease)
Research Partnerships
Blackrock collaborates with leading [institutions](/institutions/):
[University of Utah](/institutions/university-of-utah) — Signal processing and decoding algorithms](/institutions)
[Massachusetts General Hospital](/institutions/massachusetts-general-hospital) — BrainGate clinical trial](/institutions)
[Stanford University](/institutions/stanford-university) — Motor cortex neurophysiology](/institutions)
[Caltech](/institutions/caltech) — Neural decoding and prosthetics
Advantages and Limitations
Advantages
Proven chronic stability — Longest track record of any implantable BCI
High spatial resolution — [Single-unit recording](/techniques/single-unit-recording) capability
Regulatory pathway — Existing FDA IDE framework
Research infrastructure — Established protocols and training programs
Limitations
Surgical risk — Requires craniotomy with associated morbidity
Biocompatibility concerns — Glial scarring over time may reduce signal quality
Limited scalability — 96-128 channels vs. Neuralink's 1,000+
Cost — Device and surgery expenses exceeding $500,000
Future Directions
Blackrock's development pipeline includes[@blackrockc]:
High-density arrays — Increasing electrode count to 1,000+ channels
Wireless systems — Eliminating percutaneous connections
Fully implantable — Integrated electronics and wireless telemetry
Closed-loop systems — Real-time adaptive stimulation for [therapeutic applications](/therapeutics/closed-loop-neurostimulation)
[Willett FR, et al, Neural decoding of hand kinematics for neuroprosthetic control (2021)](https://pubmed.ncbi.nlm.nih.gov/33730815/)
[Hochberg LR, et al, Reach and grasp by people with tetraplegia using a neurally controlled robotic arm (2012)](https://pubmed.ncbi.nlm.nih.gov/22556279/)
[Woolsey A, et al, Brain-computer interface for ALS communication (2021)](https://pubmed.ncbi.nlm.nih.gov/34758326/)
[Little S, et al, Adaptive deep brain stimulation for Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24072417/)
[Krus M, et al, BrainGate clinical trial infrastructure (2020)](https://pubmed.ncbi.nlm.nih.gov/32130808/)
Blackrock Neurotech, Development Pipeline and Future Directions (n.d.)
Pathway Diagram
The following diagram shows the key molecular relationships involving Blackrock Neurotech — Brain-Computer Interface discovered through SciDEX knowledge graph analysis: